The weekly litigation news digest is live. Subscribe now

IP Verse

Modulation Of Apolipoprotein C-Iii (Apociii) Expression In Lipoprotein Lipase Deficient (Lpld) Populations

Patent No. EP3400947 (titled "Modulation Of Apolipoprotein C-Iii (Apociii) Expression In Lipoprotein Lipase Deficient (Lpld) Populations") was filed by Ionis Pharmaceuticals on Feb 14, 2014. The application was issued on Aug 23, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AMMELBURGMay 22, 2024FISH & RICHARDSON PC

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3400947

IONIS PHARMACEUTICALS
Application Number
EP18179911A
Filing Date
Feb 14, 2014
Status
Granted And Under Opposition
Jul 21, 2023
Publication Date
Aug 23, 2023
External Links
Slate, EP3400947B1, Google Patents